Blue Shield of California dropping CVS Health's Caremark - WSJ
Investing.com | Author Sam Boughedda
Published Aug 17, 2023 08:17AM ET
Blue Shield of California dropping CVS Health's (CVS) Caremark - WSJ
According to The Wall Street Journal, Blue Shield of California has announced it will no longer be using CVS Health's (NYSE:CVS) Caremark, its current pharmacy-benefit manager.
CVS shares are down more than 4% premarket.
The nonprofit health plan, with about 4.8 million members, instead said it would work with a select choice of companies that perform a designated function, According to the report. One of the partners includes Amazon (NASDAQ:AMZN), which will offer at-home drug delivery.
Another partner will be entrepreneur Mark Cuban's Cost Plus Drug Company. It will deliver access to low-cost medications, including through retail pharmacies, while another company, Abarca, will process drug claims.
Blue Shield reportedly said that by working with its partners, it would strive to negotiate prices with pharmaceutical makers in a different way from the typical approach in order to eliminate rebates and hidden fees.
In an interview with The Wall Street Journal, Paul Markovich, Blue Shield's chief executive officer, said, "The current pharmacy supply chain is a forest of opacity and profit," and the new setup will be "flipping that on its head."
Blue Shield believes its plan, which it is aiming to fully launch in 2025, could save it around $500 million annually, or approximately 10% to 15% of what the insurer currently spends on drugs.
Get The News You Want
Written By: Investing.com
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.